Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 667 participants.
Also called NCT01627340
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 667 participants
- Sponsor
- Registry
-
NCT01627340
-
- Other papers using this trial's data
- Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT01627340. Non-randomized; no masking; primary purpose prevention. Start 2012-07-24 (registry gives no type); primary completion 2013-12-18 (actual). Results posted on 2015-01-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
- Condition
- Hepatitis B
- Intervention (Biological)
- Engerix™-B vaccine
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01627340- Content hash
19c12115f7c2421a3c5f5312e0ad8b27d1322e1c36071b9a99978cb4d47b894b